Pediatric Oncology
Frailty associated with neurocognitive decline among young-adult cancer survivors
Treatment-associated frailty appeared associated with neurocognitive declines among a cohort of young-adult cancer survivors, according to study findings from the St. Jude Lifetime Cohort published in Journal of Clinical Oncology.
ASTRO elects three new officers
Movie ‘distraction therapy’ improves children’s experience of radiation
In the 2016 animated film “Moana,” the title character bravely battled a volcanic demon and saved her people.
Young children with brain tumors may experience cognitive difficulty before treatment
Young children with brain tumors experienced cognitive difficulties prior to adjuvant treatment, with those of a younger age at diagnosis and lower socioeconomic status at greatest risk, according to a study in Journal of Clinical Oncology.
Children’s Hospital of Philadelphia appoints leukemia specialist as section chief
Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.
Alterations in ALK gene emerge as prognostic marker for neuroblastoma survival
Genetic alterations of ALK, including clonal mutations and amplifications, in high-risk neuroblastoma demonstrated utility as independent predictors of poorer survival, according to a study published in Journal of Clinical Oncology.
Children’s Hospital of Philadelphia again named best hospital for pediatric cancer
Children’s Hospital of Philadelphia has retained its distinction as the No. 1 children’s hospital for cancer in the country.
Molecular tumor profiling beneficial in pediatric solid cancers
Molecular profiling of solid tumors in children and young adults has a significant impact on diagnosis and treatment recommendations, according to results of an interim analysis presented during the virtual ASCO Annual Meeting.
Brentuximab vedotin shows promise in high-risk pediatric Hodgkin lymphoma
The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and effective among children and adolescents with high-risk classical Hodgkin lymphoma, according to phase 2 study results.
Association of Down syndrome, AML ‘stronger than previously reported’
Down syndrome remained a significant risk factor for pediatric leukemia, especially acute myeloid leukemia, among a large modern cohort of children, according to a retrospective study published in The Journal of Pediatrics.